SURVIVAL IN CHILDREN AND ADOLESCENTS (C plus A) WITH MATURE B-NHL PROGRESSING OR RELAPSING FROM TREATMENT ON FAB/LMB 96: TUMOR BURDEN AND TIME TO RELAPSE ARE POOR PROGNOSTIC FACTORS